Harnessing Oncolytic Virus-mediated Antitumor Immunity in an Infected Cell Vaccine

Treatment of permissive tumors with the oncolytic virus (OV) VSV-Δ51 leads to a robust antitumor T-cell response, which contributes to efficacy; however, many tumors are not permissive to in vivo treatment with VSV-Δ51. In an attempt to channel the immune stimulatory properties of VSV-Δ51 and broade...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Lemay, Chantal G, Rintoul, Julia L, Kus, Agnieszka, Paterson, Jennifer M, Garcia, Vanessa, Falls, Theresa J, Ferreira, Lisa, Bridle, Byram W, Conrad, David P, Tang, Vera A, Diallo, Jean-Simon, Arulanandam, Rozanne, Le Boeuf, Fabrice, Garson, Kenneth, Vanderhyden, Barbara C, Stojdl, David F, Lichty, Brian D, Atkins, Harold L, Parato, Kelley A, Bell, John C, Auer, Rebecca C
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2012
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3437573/
https://ncbi.nlm.nih.gov/pubmed/22760544
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/mt.2012.128
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados